RCMNY
AVEO

Rubric Capital Management (New York)’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History

Rubric Capital Management (New York)’s Portfolio AVEO Stock Details AVEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,664,667
Closed -$13.7M – 106
2022
Q3 		$13.7M Buy
1,664,667
+740,782
+80% +$5.69M 0.69% 41
2022
Q2 		$6.06M Buy
+923,885
New +$4.47M 0.32% 57

Other funds holding AVEO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NAM
Nexpoint Asset Management Dallas, Texas $1.49B AUM 61.08% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Rubric Capital Management (New York)'s AVEO Position: Q4 2022 in Review

Rubric Capital Management (New York) sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q4 2022, closing a stake of 1,664,667 shares — an estimated $13.7M sold.

Rubric Capital Management (New York) first reported a position in AVEO in Q2 2022 and held it in 2 quarters. The position peaked at $13.7M in Q3 2022. 110 funds tracked by Wall St. Rank hold AVEO as of Q4 2022.

  • Rubric Capital Management (New York) reported no remaining AVEO Pharmaceuticals, Inc. position as of Q4 2022 after selling out during the quarter.
  • Rubric Capital Management (New York) sold 1,664,667 AVEO Pharmaceuticals, Inc. shares in Q4 2022, an estimated $13.7M.
  • Rubric Capital Management (New York) first reported a position in AVEO Pharmaceuticals, Inc. in Q2 2022 and held it in 2 quarters.
  • Rubric Capital Management (New York)'s AVEO Pharmaceuticals, Inc. position peaked at $13.7M in Q3 2022.
  • 110 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q4 2022.

Based on Rubric Capital Management (New York)'s 13F filing for Q4 2022, filed 10 Feb 2023.